<DOC>
	<DOC>NCT02013102</DOC>
	<brief_summary>The purpose of this study is to evaluate of the safety and efficacy of decitabine treatment of Myelodysplastic Syndrome.</brief_summary>
	<brief_title>A Phase Ⅳ Study of Decitabine in Myelodysplastic Syndrome</brief_title>
	<detailed_description>Total subjects: 240, doseⅠgroup of 120 patients, doseⅡgroup of 120 patients. Subjects are stratified randomize. If necessary, participants accepted best supportive therapy.</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Decitabine</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>Age≥18; The diagnosis of MDS patients comply WHO2008 standards; IPSS score≥0.5; WHO classification for patients RCUD, RARS and transfusiondependent RCMD; ECOG PS score: 02; Expected survival≥3 months; Serum bilirubin≤1.5*ULN, serum ALT and AST≤2.5*ULN, serum Cr≤1.5*ULN; Subjects signed informed consent form in line with GCP requirements. Can not marrow biopsy; Previously diagnosed AML; Received azacitidine or decitabine treatment any time before; Being diagnosed with other malignancies in the prior 12 months; Pregnant or lactating women; Failure to control systemic fungal, bacterial or viral infection; Known or suspected allergy to decitabine; Known human immunodeficiency virus (HIV) or hepatitis B or C classes of active viral infection; Have a history of neurological or psychiatric disorders, including epilepsy or dementia; CTCAE 3 or 4 degree peripheral neuropathy; According to the investigator's judgment, there are concomitant diseases with a serious safety hazard or affect the patients completed the study in patients; Using other experimental drugs or participating in other clinical trials in the prior one months.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>